Subscribe to RSS
DOI: 10.1055/a-0661-0287
Evidence GDF15 Plays a Role in Familial and Recurrent Hyperemesis Gravidarum
GDF15 spielt eine Rolle bei erblicher und wiederkehrender Hyperemesis gravidarumPublication History
received 13 July 2018
revised 18 July 2018
accepted 18 July 2018
Publication Date:
14 September 2018 (online)
Abstract
Introduction Hyperemesis gravidarum (HG), a pregnancy complication characterized by severe nausea and vomiting in pregnancy, occurs in up to 2% of pregnancies. It is associated with both maternal and fetal morbidity. HG is highly heritable and recurs in approximately 80% of women. In a recent genome-wide association study, it was shown that placentation, appetite, and the cachexia gene GDF15 are linked to HG. The purpose of this study was to explore whether GDF15 alleles linked to overexpression of GDF15 protein segregate with the condition in families, and whether the GDF15 risk allele is associated with recurrence of HG.
Methods We analyzed GDF15 overexpression alleles for segregation with disease using exome-sequencing data from 5 HG families. We compared the allele frequency of the GDF15 risk allele, rs16982345, in patients who had recurrence of HG with its frequency in those who did not have recurrence.
Results Single nucleotide polymorphisms (SNPs) linked to higher levels of GDF15 segregated with disease in HG families. The GDF15 risk allele, rs16982345, was associated with an 8-fold higher risk of recurrence of HG.
Conclusion The findings of this study support the hypothesis that GDF15 is involved in the pathogenesis of both familial and recurrent cases of HG. The findings may be applicable when counseling women with a familial history of HG or recurrent HG. The GDF15-GFRAL brainstem-activated pathway was recently identified and therapies to treat conditions of abnormal appetite are under development. Based on our findings, patients carrying GDF15 variants associated with GDF15 overexpression should be included in future studies of GDF15-GFRAL-based therapeutics. If safe, this approach could reduce maternal and fetal morbidity.
Zusammenfassung
Einleitung Hyperemesis gravidarum (HG), das übermäßige und anhaltende Erbrechen während der Schwangerschaft, kommt in 2% aller Schwangerschaften vor. Sie geht mit einer Erhöhung der mütterlichen und der fetalen Morbidität einher. HG ist stark vererbbar und tritt bei ungefähr 80% aller betroffenen Frauen erneut auf. In einer kürzlich durchgeführten genomweiten Assoziationsstudie konnte gezeigt werden, dass es einen Zusammenhang zwischen Plazentation, Appetit, dem Kachexie-Gen GDF15 und HG gibt. Unsere Studie wollte untersuchen, ob GDF15-Allele, die mit einer Überexpression des GDF15-Proteins einhergehen, sich in Familien zusammen mit HG vererben, und ob das GDF15-Risikoallel mit wiederkehrender HG assoziiert ist.
Methoden Die Exom-Sequenzierungsdaten von 5 Familien mit HG wurden dahingehend analysiert, ob in diesen Familien auch das GDF15-Überexpressions-Allel vererbt wurde. Die Häufigkeit des GDF15-Risikoallels rs16982345 bei Patientinnen mit wiederkehrender HG wurde mit der Häufigkeit bei Frauen ohne wiederkehrende HG verglichen.
Ergebnisse SNPs, die im Verbund mit größeren Mengen an GDF15 auftraten, vererbten sich gemeinsam mit HG in von HG betroffenen Familien. Das GDF15-Risikoallel rs16982345 ging mit einem 8-fach höheren Risiko für das Wiederauftreten von HG einher.
Schlussfolgerung Die Ergebnisse dieser Studie sprechen dafür, dass GDF15 an der Pathogenese von erblicher sowie wiederkehrender HG beteiligt ist. Das Wissen um diesen Zusammenhang könnte bei der Beratung von Frauen mit erblicher oder wiederkehrender HG von Nutzen sein. Vor Kurzem wurde der hirnstammaktivierte GDF15-GFRAL-Weg identifiziert, und es wird aktuell an Therapien zur Behandlung von abnormem Appetitverlust gearbeitet. Gestützt auf die Ergebnisse unsere Untersuchung sollten Patientinnen mit GDF15-Varianten, die mit der Überexpression von GDF15 assoziiert sind, an zukünftigen Studien zu GDF15-GFRAL-gestützten Therapeutika teilnehmen. Sollten sich diese als sicher erweisen, könnte das ein Weg sein, um die HG-bedingte mütterliche und fetale Morbidität zu verringern.
-
References
- 1 Clark SM, Costantine MM, Hankins GD. Review of NVP and HG and Early Pharmacotherapeutic Intervention. Obstet Gynecol Int 2012; 2012: 252676
- 2 Verberg MF, Gillott DJ, Al-Fardan N. et al. Hyperemesis gravidarum, a literature review. Hum Reprod Update 2005; 11: 527-539
- 3 Källén B. Hyperemesis during pregnancy and delivery outcome: a registry study. Eur J Obstet Gynecol Reprod Biol 1987; 26: 291-302
- 4 Jiang HG, Elixhauser A, Nicholas J, Steiner C, Reyes C, Bierman A. Care of Women in US Hospitals, 2000: HCUP Fact Book No. 3, no. 02-0044. Rockville, MD: Agency for Healthcare Research and Quality; 2002
- 5 Chiossi G, Neri I, Cavazutti M. et al. Hyperemesis gravidarum complicated by Wernickeʼs encephalopathy: background, case report and review of the literature. Obstet Gynecol Surv 2006; 61: 255-268
- 6 Hill JB, Yost NP, Wendel jr. GD. Acute renal failure in association with severe hyperemesis gravidarum. Obstet Gynecol 2002; 100: 1119-1121
- 7 Adams RH, Gordon J, Combes B. Hyperemesis gravidarum. I. Evidence of hepatic dysfunction. Obstet Gynecol 1968; 31: 659-664
- 8 Liang SG, Ooka F, Santo A. et al. Pneumomediastinum following esophageal rupture associated with hyperemesis gravidarum. J Obstet Gynaecol Res 2002; 28: 172-175
- 9 Fejzo MS, Poursharif B, Korst LM. et al. Symptoms and pregnancy outcomes associated with extreme weight loss among women with hyperemesis gravidarum. J Womenʼs Health 2009; 18: 1981-1987
- 10 Fejzo MS, Magtira A, Schoenberg FP. et al. Antihistamines and other prognostic factors for adverse outcome in hyperemesis gravidarum. Eur J Obstet Gynecol Reprod Biol 2013; 170: 71-76
- 11 Fejzo MS, Magtira A, Schoenberg FP. et al. Neurodevelopmental delay in children exposed in utero to hyperemesis gravidarum. Eur J Obstet Gynecol Reprod Biol 2015; 189: 79-84
- 12 Dypvik J, Pereira AL, Tanbo TG. et al. Maternal human chorionic gonadotrophin concentrations in very early pregnancy and risk of hyperemesis gravidarum: A retrospective cohort study of 4372 pregnancies after in vitro fertilization. Eur J Obstet Gynecol Reprod Biol 2018; 221: 12-16
- 13 Zhang Y, Cantor R, MacGibbon K. et al. Familial aggregation of hyperemesis gravidarum. Am J Obstet Gynecol 2011; 204: 230
- 14 Colodro-Conde L, Jern P, Johansson A. et al. Nausea and vomiting during pregnancy is highly heritable. Behav Genet 2016; 46: 481-491
- 15 Fejzo MS, Sazonova OV, Sathirapongsasuti JF. et al. Placenta and appetite genes GDF15 and IGFBP7 are associated with hyperemesis gravidarum. Nat Commun 2018; 9: 1178
- 16 Moore AG, Brown DA, Fairlie WD. et al. The transforming growth factor-ss superfamily cytokine macrophage inhibitory cytokine-1 is present in high concentrations in the serum of pregnant women. J Clin Endocrinol Metab 2000; 85: 4781-4788
- 17 Tsai VW, Macia L, Johnen H. et al. TGF-b superfamily cytokine MIC-1/GDF15 is a physiological appetite and body weight regulator. PLoS One 2013; 8: e55174
- 18 Lerner L, Tao J, Liu Q. et al. MAP3K11/GDF15 axis is a critical driver of cancer cachexia. J Cachexia Sarcopenia Muscle 2016; 7: 467-482
- 19 Hsu JY, Crawley S, Chen M. et al. Non-homeostatic body weight regulation through a brainstem-restricted receptor for GDF15. Nature 2017; 550: 255-259
- 20 Hyperemesis Education and Research Foundation. Online: http://www.helpher.org last access: 07.08.2018
- 21 Fejzo MS, Myhre R, Colodro-Conde L. et al. Genetic analysis of Hyperemesis Gravidarum reveals association with intracellular calcium release channel (RYR2). Mol Cell Endocrinol 2017; 439: 308-316
- 22 Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 2009; 25: 1754
- 23 McKenna A, Hanna M, Banks E. et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res 2010; 20: 1297
- 24 Hsu LA, Wu S, Juang JJ. et al. Growth Differentiation Factor 15 May Predict Mortality of Peripheral and Coronary Artery Diseases and Correlate with Their Risk Factors. Mediators Inflamm 2017; 2017: 9398401
- 25 Lappalainen T, Sammeth M, Friedländer MR. et al. Transcriptome and genome sequencing uncovers functional variation in humans. Nature 2013; 501: 506-511
- 26 Eriksson N, Johansson A, Hagstrom E. et al. Genetic Effects on Levels of Growth Differentiation Factor 15 – A PLATO Genomics Study. Boston: Annual Meeting of the American Society of Human Genetics; 2013
- 27 Segerer SE, Rieger L, Kapp M. et al. MIC-1 (a multifunctional modulator of dendritic cell phenotype and function) is produced by decidual stromal cells and trophoblasts. Hum Reprod 2012; 27: 200-209
- 28 Tong S, Marjono B, Brown DA. et al. Serum concentrations of macrophage inhibitory cytokine 1 (MIC1) as a predictor of miscarriage. Lancet 2004; 363: 129-130
- 29 Xiong J, Walker K, Min X. et al. Long-acting MIC-1/GDF15 molecules to treat obesity: evidence from mice to monkeys. Sci Transl Med 2017; 9: eaan8732
- 30 Marjono AB, Brown DA, Horton KE. et al. Macrophage inhibitory cytokine-1 in gestational tissues and maternal serum in normal and pre-eclamptic pregnancy. Placenta 2003; 24: 100-106
- 31 Fejzo M, Arzy D. et al. 23andMe Research Team. Genetic Analysis of Hyperemesis Gravidarum. Windsor, England, International Colloquium on Hyperemesis Gravidarum, Oct. 2017. Online: https://vimeo.com/260389622 last access: 07.08.2018